ALDX: Aldeyra Therapeutics Inc

ALDX Notícias

• 21:05 12 Health Care Stocks Moving In Friday's After-Market Session
• 13:33 RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
• 12:59 Here's Why You Should Add ANRO Stock to Your Portfolio Now
• 12:52 Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
• 15:24 Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
• 14:55 PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
• 16:55 argenx Meets Primary Endpoint in Phase II Celiac Disease Study
• 14:53 EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
• 13:57 Here's Why You Should Add LPCN Stock to Your Portfolio Now
• 13:49 Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
• 15:08 ETON Stock Surges 108% in Six Months: Here's What You Need to Know
• 21:05 12 Health Care Stocks Moving In Tuesday's After-Market Session
• 13:55 AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
• 13:30 PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
• 17:05 12 Health Care Stocks Moving In Monday's Intraday Session
• 14:46 Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
• 14:36 Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
• 13:42 Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
• 12:10 H.C. Wainwright mantém recomendação neutra para Aldeyra com preço-alvo de US$ 2,00
• 10:14 HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target
• 08:02 Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow (NASDAQ:ALDX) 2026-09-30
• 18:34 Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
• 16:30 BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target
• 14:12 Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline